• 1
    Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:29412948.
  • 2
    Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated dilatation in obese subjects. Hypertension. 2000;36:430435.
  • 3
    Dandona P, Ghanim H, Chaudhuri A, Mohanty P. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. J Diabetes Complications. 2008;22:6265.
  • 4
    Dandona P, Chaudhuri A, Ghanim H. Rosiglitazone, thiazolidinediones and atherosclerosis. Atherosclerosis. 2010;211(2):384385.
  • 5
    Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:34523456.
  • 6
    Gerstein HC, Ratner RE, Cannon CP, et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetic patients with cardiovascular history trial. Circulation. 2010;121:11761187.
  • 7
    Nissen SE, Nicholls DJ, Wolski K, et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes; the PERISCOPE trial. JAMA. 2008;299:15611573.
  • 8
    Dormandy JA, Charbonnel M, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macrovascular Events): a randomized controlled trial. Lancet. 2005;366:12791289.
  • 9
    Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:25722581.
  • 10
    Graham DH, Oueller-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411418.
  • 11
    Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009;339:B2942.
  • 12
    Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effects of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:20972104.
  • 13
    Linkoff AM, Wolski K, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:11801188.
  • 14
    Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs. pioglitazone therapy. Arch Intern Med. 2008;168:23682375.
  • 15
    Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA. 2007;298:11891195.
  • 16
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:24572471.
  • 17
    Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk of myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147:578581.
  • 18
    Nissen SE, Wolski K. Rosiglitazone revisited. An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Ann Intern Med. 2010;170:11911201. June 28 [online].
  • 19
    Home PD, Pocock SJ, Beck-Nielsen H. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet. 2009;373:21252135.
  • 20
    Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks. A science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010;121:18681877.
  • 21
    The Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:15451559.
  • 22
    Staff Report of the GlaxoSmithKline and the Diabetes Drug Avandia. Prepared by the staff of the Committee on Finance, United States Senate, Max Baucus, Chairman, Chuck Grassley, Ranking member.
  • 23
    DeAngelis CD, Fontanarosa PB. Ensuring integrity in industry-sponsored research. Primum non nocere, revisited. JAMA. 2010;303:11961198.
  • 24
    Juurlink DN. Rosiglitazone and the case for safety over certainty. JAMA. 2010;304:469471.
  • 25
    Nissen SD. Setting the RECORD straight. JAMA. 2010;303:11941195.